1-13 of 13
Michael Gordon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Tae Won Kim, Howard A. Burris, III, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Jr, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3452–3463.
https://doi.org/10.1158/1078-0432.CCR-21-4020
Published: 15 August 2022
View article titled, First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Open the PDF for First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John Powderly, Lauren C. Harshman, Paul Conkling, Jean-Pierre Delord, Michael Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, III, Sanjeev Mariathasan, Carol O'Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3360–3369.
https://doi.org/10.1158/1078-0432.CCR-20-1981
Published: 15 June 2021
View article titled, Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Open the PDF for Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Ani S. Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio González-García, Nathan Standifer, Jennifer Cann, Nicholas Durham, Shahram Rahimian, Rakesh Kumar, Crystal S. Denlinger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6196–6203.
https://doi.org/10.1158/1078-0432.CCR-20-0452
Published: 01 December 2020
View article titled, Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3220–3228.
https://doi.org/10.1158/1078-0432.CCR-18-2740
Published: 03 June 2019
View article titled, Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Open the PDF for Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors in another window
Journal Articles

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Manish A. Shah, Alexander Starodub, Sunil Sharma, Jordan Berlin, Manish Patel, Zev A. Wainberg, Jorge Chaves, Michael Gordon, Kevin Windsor, Carrie Baker Brachmann, Xi Huang, Greg Vosganian, Julia D. Maltzman, Victoria Smith, Jeffrey A. Silverman, Heinz-Josef Lenz, Johanna C. Bendell
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (16): 3829–3837.
https://doi.org/10.1158/1078-0432.CCR-17-2469
Published: 14 August 2018
View article titled, Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Open the PDF for Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Antonio Jimeno, Michael Gordon, Rashmi Chugh, Wells Messersmith, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Shailaja Uttamsingh, Rainer K. Brachmann, David C. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7490–7497.
https://doi.org/10.1158/1078-0432.CCR-17-2157
Published: 14 December 2017
View article titled, A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (21): 6020–6029.
https://doi.org/10.1158/1078-0432.CCR-13-0953
Published: 31 October 2013
View article titled, A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
Open the PDF for A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

William P. Tew, Michael Gordon, John Murren, Jakob Dupont, Sandra Pezzulli, Carol Aghajanian, Paul Sabbatini, David Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 358–366.
https://doi.org/10.1158/1078-0432.CCR-09-2103
Published: 04 January 2010
View article titled, Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
Open the PDF for Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors in another window
Journal Articles

Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models

Wendy L. Allen, Vicky M. Coyle, Puthen V. Jithesh, Irina Proutski, Leanne Stevenson, Cathy Fenning, Daniel B. Longley, Richard H. Wilson, Michael Gordon, Heinz-Josef Lenz, Patrick G. Johnston
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6647–6655.
https://doi.org/10.1158/1078-0432.CCR-08-0452
Published: 16 October 2008
View article titled, Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models
Open the PDF for Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models in another window
Includes: Supplementary data
Journal Articles

Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma

Scot Ebbinghaus, Maha Hussain, Nizar Tannir, Michael Gordon, Apurva A. Desai, Raymond A. Knight, Rod A. Humerickhouse, Jiang Qian, Gary B. Gordon, Robert Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22): 6689–6695.
https://doi.org/10.1158/1078-0432.CCR-07-1477
Published: 15 November 2007
View article titled, Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Open the PDF for Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma in another window
Journal Articles

Epidermal Growth Factor Receptor Gene Polymorphisms Predict Pelvic Recurrence in Patients with Rectal Cancer Treated with Chemoradiation

Wu Zhang, David J. Park, Bo Lu, Dong Yun Yang, Michael Gordon, Susan Groshen, Jim Yun, Oliver A. Press, Daniel Vallböhmer, Katrin Rhodes, Heinz-Josef Lenz
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (2): 600–605.
https://doi.org/10.1158/1078-0432.600.11.2
Published: 08 February 2005
View article titled, Epidermal Growth Factor Receptor Gene Polymorphisms Predict Pelvic Recurrence in Patients with Rectal Cancer Treated with Chemoradiation
Open the PDF for Epidermal Growth Factor Receptor Gene Polymorphisms Predict Pelvic Recurrence in Patients with Rectal Cancer Treated with Chemoradiation in another window
Journal Articles

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

Alan Sandler, Michael Gordon, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Ajai Chaudhary, Karen Fife, Linda Battiato, Christopher Sweeney, Christopher Jordan, Michael Burgess, Christopher A. Slapak
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3265–3272.
https://doi.org/10.1158/1078-0432.CCR-03-0644
Published: 24 May 2004
View article titled, A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy
Open the PDF for A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy in another window
Journal Articles

Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study

Janice P. Dutcher, Theodore Logan, Michael Gordon, Jeffrey Sosman, Geoffrey Weiss, Kim Margolin, Terry Plasse, James Mier, Michael Lotze, Joseph Clark, Michael Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3442–3450.
Published: 01 September 2000
View article titled, Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study
Open the PDF for Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study in another window